tiprankstipranks
Trending News
More News >

Lixte Biotechnology Closes $1.5M Direct Offering

Story Highlights
Lixte Biotechnology Closes $1.5M Direct Offering

Don’t Miss TipRanks’ Half-Year Sale

Lixte Biotechnology Holdings ( (LIXT) ) has issued an update.

On July 8, 2025, Lixte Biotechnology Holdings, Inc. announced the closing of a $1.5 million registered direct offering with accredited investors, involving the sale of shares of Common Stock or Pre-Funded Warrants. The proceeds from this offering are intended for general corporate purposes and working capital, potentially impacting the company’s operational capabilities and market positioning in the pharmaceutical industry.

More about Lixte Biotechnology Holdings

Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies. The company is pioneering a new field of cancer biology called activation lethality, with its lead compound, LB-100, which is a first-in-class PP2A inhibitor. Lixte’s approach is supported by a comprehensive patent portfolio, and proof-of-concept clinical trials are underway for various cancers.

Average Trading Volume: 1,992,205

Technical Sentiment Signal: Hold

Current Market Cap: $6.01M

See more data about LIXT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1